Aptose Biosciences (TSE:APS) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$2.27 and traded as high as C$2.34. Aptose Biosciences shares last traded at C$2.34, with a volume of 156 shares traded.

Aptose Biosciences Price Performance

The company has a quick ratio of 5.41, a current ratio of 0.69 and a debt-to-equity ratio of -103.31. The stock has a market cap of C$5.97 million, a P/E ratio of -0.22 and a beta of -1.24. The firm has a 50 day moving average price of C$2.27 and a 200 day moving average price of C$2.19.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings data on Tuesday, March 31st. The biotechnology company reported C($4.07) earnings per share (EPS) for the quarter. On average, analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.